A carregar...
PD-1/PD-L1 Pathway Inhibitors in Advanced Prostate Cancer
INTRODUCTION: Pharmacological inhibition of immune checkpoint receptors or their ligands represents a transformative breakthrough in the management of multiple cancers. However, immune checkpoint inhibitors have yet to be FDA-approved for the management of metastatic prostate cancer (PCa), the commo...
Na minha lista:
| Publicado no: | Expert Rev Clin Pharmacol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6317331/ https://ncbi.nlm.nih.gov/pubmed/29641940 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/17512433.2018.1464388 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|